A Phase II Study of SNX-5422 in Patients with Select Advanced HER2 Cancers

Protocol
13-112
Full Title
A Single Arm Study of SNX-5422 in Subjects with HER2 Positive or HER2 Mutated Cancers
Phase
II
Purpose

HER2 is a protein that fuels cancer growth and is active in several types of cancer. SNX-5422 is an investigational drug designed to fight cancer by inhibiting HER2. SNX-5422 is taken orally (by mouth).

The purpose of this study is to evaluate the safety and effectiveness of SNX-5422 in patients with HER2-positive cancers of the breast, esophagus, stomach, lung (non-small cell), bladder, or other urothelial cancers that have spread despite other treatments.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have HER2-positive cancers of the breast, esophagus, stomach, lung (non-small cell), bladder, or other urothelial cancers that have spread despite other treatments.
  • Patients should have had at least one but no more than five prior regimens of therapy.
  • Patients with breast and esophagogastric cancers must have experienced continued cancer growth despite prior treatment with trastuzumab.
  • At least 4 weeks must have passed since completion of prior therapies and entry into the study.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Martin Voss at 646-422-4631.

Disease(s)
Kidney Cancer
Lung Cancer, Non-Small Cell
Upper Gastrointestinal: Esophageal Cancer
Upper Gastrointestinal: Gastric Cancer
Locations